La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Quest Diagnostics Gestione
Gestione criteri di controllo 4/4
Quest Diagnostics' Il CEO è Jim Davis, nominato in Nov2022, e ha un mandato di 1.75 anni. la retribuzione annua totale è $ 12.67M, composta da 9.3% di stipendio e 90.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.067% delle azioni della società, per un valore di $ 11.31M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.7 anni e 5 anni.
Informazioni chiave
Jim Davis
Amministratore delegato
US$12.7m
Compenso totale
| Percentuale dello stipendio del CEO | 9.3% |
| Mandato del CEO | 1.8yrs |
| Proprietà del CEO | 0.07% |
| Durata media del management | 3.7yrs |
| Durata media del Consiglio di amministrazione | 5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12
Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Quest Diagnostics Q4 2022 Earnings Preview
Feb 01Quest Diagnostics' unit Pack Health to expand Alabama facility
Jan 17Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 17Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)
Jan 03An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued
Dec 04Quest Diagnostics declares $0.66 dividend
Nov 14Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Nov 06Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
| Sep 30 2019 | n/a | n/a | US$709m |
| Jun 30 2019 | n/a | n/a | US$707m |
| Mar 31 2019 | n/a | n/a | US$720m |
| Dec 31 2018 | US$3m | US$590k | US$733m |
| Sep 30 2018 | n/a | n/a | US$860m |
| Jun 30 2018 | n/a | n/a | US$808m |
| Mar 31 2018 | n/a | n/a | US$782m |
| Dec 31 2017 | US$3m | US$590k | US$769m |
Compensazione vs Mercato: La retribuzione totale di Jim ($USD 12.67M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 13.21M ).
Compensazione vs guadagni: La retribuzione di Jim è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Jim Davis (61 yo)
1.8yrs
Mandato
US$12,673,834
Compensazione
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 1.8yrs | US$12.67m | 0.067% $ 11.3m | |
| Executive VP & CFO | 2.1yrs | US$3.98m | 0.016% $ 2.6m | |
| Senior VP & General Counsel | 25yrs | US$2.25m | 0.035% $ 5.8m | |
| Executive Vice President of Regional Businesses | no data | US$3.16m | 0.058% $ 9.8m | |
| Senior Vice President of Clinical Solutions | 2yrs | US$2.02m | 0.014% $ 2.3m | |
| Senior VP | 5.3yrs | Nessun dato | 0.032% $ 5.4m | |
| Senior VP | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Compliance Officer | 1.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Communications Officer | 27.8yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | 6.5yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Strategy | 8.5yrs | Nessun dato | Nessun dato |
3.7yrs
Durata media
61yo
Età media
Gestione esperta: Il team dirigenziale di DGX è considerato esperto (durata media dell'incarico 3.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 1.8yrs | US$12.67m | 0.067% $ 11.3m | |
| Independent Director | 10.6yrs | US$315.44k | 0.023% $ 3.8m | |
| Director | less than a year | Nessun dato | Nessun dato | |
| Lead Independent Director | 12.7yrs | US$345.94k | Nessun dato | |
| Independent Director | 19.7yrs | US$342.12k | Nessun dato | |
| Independent Director | 5.5yrs | US$312.33k | 0.0026% $ 434.0k | |
| Independent Director | 10.1yrs | US$315.73k | 0.016% $ 2.7m | |
| Independent Director | 4.4yrs | US$300.44k | Nessun dato | |
| Independent Director | 3yrs | US$300.44k | Nessun dato | |
| Independent Director | 1.3yrs | US$280.41k | Nessun dato |
5.0yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di DGX sono considerati esperti (durata media dell'incarico 5 anni).